BR112018074941A2 - combinações farmacêuticas - Google Patents

combinações farmacêuticas

Info

Publication number
BR112018074941A2
BR112018074941A2 BR112018074941-9A BR112018074941A BR112018074941A2 BR 112018074941 A2 BR112018074941 A2 BR 112018074941A2 BR 112018074941 A BR112018074941 A BR 112018074941A BR 112018074941 A2 BR112018074941 A2 BR 112018074941A2
Authority
BR
Brazil
Prior art keywords
pharmaceutically acceptable
pharmaceutical combinations
acceptable salt
inhibitor
egfr
Prior art date
Application number
BR112018074941-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Caponigro Giordano
Alexander Cao Zhu
Original Assignee
Caponigro Giordano
Alexander Cao Zhu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60477982&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112018074941(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Caponigro Giordano, Alexander Cao Zhu filed Critical Caponigro Giordano
Publication of BR112018074941A2 publication Critical patent/BR112018074941A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112018074941-9A 2016-06-03 2017-06-02 combinações farmacêuticas BR112018074941A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662345389P 2016-06-03 2016-06-03
US62/345,389 2016-06-03
PCT/US2017/035653 WO2017210538A1 (en) 2016-06-03 2017-06-02 Pharmaceutical combinations

Publications (1)

Publication Number Publication Date
BR112018074941A2 true BR112018074941A2 (pt) 2019-03-12

Family

ID=60477982

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018074941-9A BR112018074941A2 (pt) 2016-06-03 2017-06-02 combinações farmacêuticas

Country Status (26)

Country Link
US (3) US10485788B2 (https=)
EP (1) EP3463345B1 (https=)
JP (2) JP6805336B2 (https=)
KR (1) KR102439911B1 (https=)
CN (1) CN109890386B (https=)
AU (1) AU2017275650B2 (https=)
BR (1) BR112018074941A2 (https=)
CA (1) CA3026361A1 (https=)
CL (1) CL2018003421A1 (https=)
CO (1) CO2019000010A2 (https=)
CR (1) CR20190002A (https=)
DK (1) DK3463345T3 (https=)
FI (1) FI3463345T3 (https=)
HU (1) HUE060653T2 (https=)
IL (1) IL263431A (https=)
MA (1) MA45187A (https=)
MX (1) MX387795B (https=)
PH (1) PH12018502549A1 (https=)
PL (1) PL3463345T3 (https=)
PT (1) PT3463345T (https=)
RU (1) RU2759669C2 (https=)
SG (1) SG11201810793XA (https=)
SI (1) SI3463345T1 (https=)
UA (1) UA125436C2 (https=)
WO (1) WO2017210538A1 (https=)
ZA (1) ZA201900019B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX387795B (es) 2016-06-03 2025-03-19 Array Biopharma Inc Combinaciones farmaceuticas.
AU2017329090B9 (en) 2016-09-19 2019-09-05 Novartis Ag Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor
ES2952265T3 (es) 2017-05-02 2023-10-30 Novartis Ag Terapia combinada que comprende un inhibidor de Raf y trametinib
ES3025633T3 (en) 2019-05-13 2025-06-09 Novartis Ag New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
CA3150474A1 (en) * 2019-10-11 2021-04-15 Geraint Iwan Davies Drug dosage determination devices and methods
WO2021163072A1 (en) * 2020-02-10 2021-08-19 Cedars-Sinai Medical Center Method of treating pancreatic cancer
JP7288220B2 (ja) 2021-03-29 2023-06-07 ダイキン工業株式会社 モータ、送風装置、および冷凍装置
WO2023230554A1 (en) 2022-05-25 2023-11-30 Pfizer Inc. Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer
CN120359214A (zh) * 2022-12-15 2025-07-22 豪夫迈·罗氏有限公司 用于癌症治疗的组合疗法
WO2025003956A1 (en) 2023-06-30 2025-01-02 Pfizer Inc. High drug loading formulations of encorafenib

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
AU6267896A (en) 1995-06-07 1996-12-30 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth oftumors
SG2013013339A (en) 2002-03-13 2014-12-30 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
US7235537B2 (en) * 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
WO2008120004A1 (en) 2007-04-02 2008-10-09 Astrazeneca Ab Combination of a mek- inhibitor and a b-raf inhibitor for the treatment of cancer
SI2324008T1 (sl) 2008-07-24 2012-08-31 Nerviano Medical Sciences Srl 3,4-diarilpirazoli kot protein-kinazni inhibitorji
JP5527878B2 (ja) * 2009-07-30 2014-06-25 トムソン ライセンシング 表示装置及び音声出力装置
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
CA2838736A1 (en) * 2011-06-07 2012-12-13 Caris Mpi, Inc. Molecular profiling for cancer
CN108542906A (zh) * 2011-11-11 2018-09-18 诺华股份有限公司 治疗增生性疾病的方法
ES2695099T3 (es) 2011-11-23 2019-01-02 Array Biopharma Inc Formulaciones farmacéuticas
AR091876A1 (es) * 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
TR201904980T4 (tr) * 2012-08-07 2019-05-21 Novartis Ag Bir B-Raf inhibitörü, bir EGFR inhibitörü ve isteğe bağlı olarak bir PI3K-alfa inhibitörü içeren farmasötik kombinasyonlar.
AR099630A1 (es) * 2012-10-19 2016-08-10 Novartis Ag Preparación de un inhibidor de mek y formulación que lo comprende
US20150273057A1 (en) * 2012-10-25 2015-10-01 Glaxosmithkline Llc Combination
UA118846C2 (uk) 2013-03-21 2019-03-25 Новартіс Аг Комбінована терапія
WO2015008729A1 (ja) * 2013-07-18 2015-01-22 株式会社ダイセル 酸化物の製造方法
US20150087279A1 (en) * 2013-09-20 2015-03-26 Better Mousetrap, LLC Mobile accident processing system and method
CN106029074A (zh) * 2013-12-12 2016-10-12 诺华股份有限公司 用于治疗癌症的曲美替尼、帕尼单抗和达拉菲尼组合
CN105566225A (zh) * 2015-02-16 2016-05-11 苏州晶云药物科技有限公司 一种口服丝裂原活化蛋白激酶抑制剂的晶型及其制备方法
WO2016155670A1 (zh) * 2015-04-01 2016-10-06 苏州晶云药物科技有限公司 一种cdk抑制剂和mek抑制剂的共晶及其制备方法
WO2017019279A1 (en) 2015-07-27 2017-02-02 Southern Research Institute Methods and compositions to treat cancers involving egfr
MX387795B (es) 2016-06-03 2025-03-19 Array Biopharma Inc Combinaciones farmaceuticas.

Also Published As

Publication number Publication date
MX387795B (es) 2025-03-19
JP6805336B2 (ja) 2020-12-23
HUE060653T2 (hu) 2023-04-28
CL2018003421A1 (es) 2019-07-19
PT3463345T (pt) 2023-01-06
KR102439911B1 (ko) 2022-09-05
JP2019525948A (ja) 2019-09-12
US20190105303A1 (en) 2019-04-11
US20200230108A1 (en) 2020-07-23
EP3463345A4 (en) 2020-02-26
CN109890386B (zh) 2022-05-24
CA3026361A1 (en) 2017-12-07
JP2021054832A (ja) 2021-04-08
SG11201810793XA (en) 2018-12-28
CO2019000010A2 (es) 2019-05-21
AU2017275650B2 (en) 2023-06-01
EP3463345B1 (en) 2022-11-02
US20230044943A1 (en) 2023-02-09
AU2017275650A1 (en) 2019-01-17
PL3463345T3 (pl) 2023-02-06
PH12018502549A1 (en) 2019-04-08
WO2017210538A1 (en) 2017-12-07
RU2018146812A (ru) 2020-07-09
CR20190002A (es) 2019-06-10
UA125436C2 (uk) 2022-03-09
DK3463345T3 (da) 2023-01-09
KR20190119507A (ko) 2019-10-22
SI3463345T1 (sl) 2023-02-28
US10485788B2 (en) 2019-11-26
FI3463345T3 (fi) 2023-01-31
US11376239B2 (en) 2022-07-05
MA45187A (fr) 2019-04-10
CN109890386A (zh) 2019-06-14
RU2759669C2 (ru) 2021-11-16
IL263431A (en) 2019-01-31
RU2018146812A3 (https=) 2020-10-09
EP3463345A1 (en) 2019-04-10
ZA201900019B (en) 2023-04-26
MX2018014973A (es) 2019-12-18

Similar Documents

Publication Publication Date Title
BR112018074941A2 (pt) combinações farmacêuticas
AR100215A1 (es) Conjugados de anticuerpo-fármaco anti-ptk7
MX2018010473A (es) Terapia de combinacion con anticuerpos anti cumulo de diferenciacion 73 (cd73).
EA201700181A1 (ru) Композиции аденозиндеаминазы-2 (ада-2), их варианты и способы использования
MX2018009581A (es) Inmunoglobulina con fabs en tandem y sus usos.
MX2021006571A (es) Inhibidores de tirosina-cinasas.
CL2014001547A1 (es) Compuestos derivados de benzotienilo-pirrolotriazina, como inhibidores de la proteina tirosina quinasa; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para el tratamiento y/o la prevencion de cancer y enfermedades tumorales.
PH12018501153A1 (en) Novel anti-claudin antibodies and methods of use
JO3589B1 (ar) مثبطات كيناز البروتين c وطرق استخداماتها
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CL2016001895A1 (es) Compuestos
UA118354C2 (uk) Антитіло до рецептора колонієстимулювального фактора (кфс-1r)
BR112017026535A2 (pt) composto de fórmula estrutural i, enantiômero isolado, composição farmacêutica, método para inibir atividade do transportador de monocarboxilato mct4, método para inibir seletivamente atividade do transportador de monocarboxilato mct4, método para tratar um distúrbio mediado por transportador de monocarboxilato mct4 e uso de um composto
BR112016008146A2 (pt) Anticorpo isolado, ácido nucleico isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, métodos para detectar um câncer, de identificação e de seleção de um paciente com câncer
BR112017027721A2 (pt) formulação de alta concentração
BR112018011177A2 (pt) conjugados de citarabina para terapia de câncer
MX2018015172A (es) Metodos para tratar cancer pancreatico.
CO2020005485A2 (es) Administración oral de análogos del péptido glp-1
EP4570317A3 (en) Compounds for the treatment of bovine or swine respiratory disease
BR112017014416A2 (pt) sal de mangiferina-6-o-berberina e método de preparação e uso do mesmo
HK1250626A1 (zh) 借助塞里班土单抗的组合治疗
CO2017000687A2 (es) Derivados de cromeno sustituidos como inhibidores duales selectivos de proteínas cinasas pi3 delta y gamma
MX390967B (es) Composiciones y métodos para la modulación de la actividad at2r
AR105553A1 (es) Anticuerpo del receptor del factor 1 del crecimiento similar a insulina (igf-1r) y su utilización para diagnosticar cáncer
AR106773A1 (es) Conjugados de fármaco de anticuerpo her2 específicos de sitio

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]